Qyuns Therapeutics Reports Positive Phase III Results for Crusekitug in Ankylosing Spondylitis
Reuters
Oct 28
Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase III Results for Crusekitug in Ankylosing Spondylitis
Qyuns Therapeutics Co., Ltd. announced that the Phase III clinical trial results for Crusekitug (QX002N), a drug developed for the treatment of ankylosing spondylitis, were presented at the 2025 annual meeting of the American College of Rheumatology (ACR Convergence) in Chicago. The multicenter, randomized, double-blind, placebo-controlled study involved 641 patients across 58 research centers in China. The trial demonstrated that at week 16, the ASAS40 response rate in the Crusekitug group was 40.4%, compared to 18.9% in the placebo group, with statistical significance (P < 0.0001). The ASAS20 response rate for Crusekitug was 65.2%, also significantly higher than the placebo group. The study included a 48-week treatment period and a 4-week safety follow-up.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.